LONDON, June 28, 2016 -- Stolt-Nielsen Limited (Oslo Børs: SNI) announced today that a presentation and conference call to discuss the Company's unaudited results for the second quarter of 2016 will be held on Thursday, July 7, 2016 at 3:00pm CEST (9:00am EDT, 2:00pm BST) in the auditorium at Swedbank, Filipstad Brygge 1, 0115, in Oslo, Norway.
The presentation and conference call will be hosted by:
- Mr. Niels G. Stolt-Nielsen - Chief Executive Officer, Stolt-Nielsen Limited
- Mr. Jan Chr. Engelhardtsen - Chief Financial Officer, Stolt-Nielsen Limited
Those who wish to participate may dial +44 20 34 271 900 (UK), +1 646 254 3367 (US & Canada) or +47 23 162 729 (Norway) and quote the code: 5309470. Phone lines will open 10 minutes before the call. A live audio webcast of the presentation may be accessed via the Stolt-Nielsen website at:
http://www.stolt-nielsen.com/en/Investor-Relations/Earnings-Release-Presentations.aspx.
For additional information please contact:
Jan Chr. Engelhardtsen
Chief Financial Officer
UK +44 (0) 20 7611 8972
[email protected]
Jens F. Grüner-Hegge
V.P. Corporate Finance
UK +44 (0) 20 7611 8985
[email protected]
About Stolt-Nielsen Limited
Stolt-Nielsen Limited (SNL or the "Company") is a leading global provider of integrated transportation solutions for bulk liquid chemicals, edible oils, acids, and other specialty liquids through its three largest business divisions, Stolt Tankers, Stolthaven Terminals and Stolt Tank Containers. Stolt Sea Farm produces and markets high quality turbot, sole, sturgeon, and caviar. Stolt-Nielsen Gas develops opportunities in LPG and LNG shipping and distribution. Stolt-Nielsen Limited is listed on the Oslo Stock Exchange.
HUG#2023635


Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Italy Fines Apple €98.6 Million Over App Store Dominance
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 



